2BBBullish & Bearish
Regeneron Pharmaceuticals, Inc. (REGN) trades on NASDAQ. It operates in the Health Care sector, Biotechnology industry. Its current 2BB score is 32 out of 100.
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.
Regeneron Pharmaceuticals, Inc.’s current 2BB score is 32 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 12 | Very Low |
| Momentum | 48 | Stable |
| Financial strength | 50 | Normal |
| Quality | 100 | Very Strong |
| Risk | 0 | Very Low |
| CEO | Leonard Schleifer |
| Headquarters | Tarrytown, New York, United States |
| Founded | 1988 |
| Employees | 15.3K |
| P/E ratio | 15.41 |
| 52-week range | $529.69 – $821.11 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2027-01-28 | — | 15.8695 | — | $4.73B |
| 2026-10-26 | — | 16.2132 | — | $4.64B |
| 2026-07-30 | — | 10.6694 | — | $3.89B |
| 2026-04-27 | — | 9.2916 | — | $3.52B |